HCM catalysts
Catalysts and events linked to HCM, newest first.
HCM stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer 2026-09-29 · Up | regulatory milestone achievement and future US commercial royalties | AstraZeneca submitted US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer | Not recorded |
| AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer 2026-09-29 · Up | milestone cash flows and US commercial royalty visibility on FDA regulatory advancement | AstraZeneca submitted US NDA for savolitinib (ORPATHYS) partnered with HUTCHMED | Not recorded |
| AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer 2026-09-29 · Up | regulatory milestone progress toward US commercial launch of savolitinib | AstraZeneca submitted US NDA for savolitinib combined with osimertinib | Not recorded |
| HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate 2026-09-28 · Up | clinical pipeline milestone progression and milestone fee eligibility | First patient dosed in Phase Ia global trial of HMPL-A830 | Not recorded |
| HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830 2026-09-28 · Up | first-in-class clinical trial progression and milestone pipeline optionality | HUTCHMED initiated a Phase Ia global clinical trial of HMPL-A830 with first patient dosed September 24, 2026. | Not recorded |
| HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid Tumors 2026-09-28 · Up | clinical milestone progression in partnered oncology pipeline | First patient dosed on September 24, 2026, in Phase Ia study of HMPL-A830. | Not recorded |
| HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026 2026-09-24 · Up | clinical pipeline validation and milestone royalty visibility | Phase III SAFFRON and SANOVO studies demonstrate statistically significant results in NSCLC. | Not recorded |
| HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO 2026-09-24 · Up | milestone and royalty monetization via AstraZeneca partnership | Source confirms Phase III SAFFRON and SANOVO data presentations scheduled for ESMO 2026. | Not recorded |
Do these developments change your position?
Review HCM alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
See today's live cards
1 live catalyst on HCM is in Desk now. Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.
DateCardAvg 5d
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-28HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate TherapyHCM+0.14%
- 2026-09-28HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830HCM+0.14%
- 2026-09-28HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830HCM+0.14%
- 2026-09-28HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830HCM+0.14%
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
- 2026-09-28HUTCHMED Begins Global Phase Ia Trial for KRAS-EGFR Conjugate HMPL-A830GSK HCM+0.14%
- 2026-09-28HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid TumorsGSK HCM+0.14%
- 2026-09-28HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR ConjugateGSK HCM+0.14%
- 2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMOAZN HCM+4.82%
- 2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressAZN HCM+4.82%
- 2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026AZN HCM+4.82%
- 2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMOAZN HCM+4.82%
- 2026-09-24HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026AZN HCM+4.82%
- 2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 CongressAZN HCM+4.82%
- 2026-09-24HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026AZN HCM+4.82%
- 2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMOAZN HCM+4.82%
- 2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMOAZN HCM+4.82%
- 2026-09-24HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026AZN HCM+4.82%
- 2026-08-31HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLCAZN HCM+14.52%
- 2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial dataAZN HCM+14.52%
- 2026-08-31HUTCHMED and AstraZeneca Announce Positive Phase III SANOVO Trial in NSCLCAZN HCM+14.52%
- 2026-08-31HUTCHMED and AstraZeneca report positive Phase III trial for Orpathys plus TagrissoAZN HCM+14.52%
- 2026-08-31HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial dataAZN HCM+14.52%
- 2026-08-31HUTCHMED and AstraZeneca Report Positive Phase III SANOVO Trial in ChinaAZN HCM+14.52%
- 2026-08-28China NMPA grants conditional approval for HUTCHMED's ATLED in oncologyHCM+13.81%
- 2026-08-28HUTCHMED Receives NMPA Conditional Approval for ATLED in ChinaHCM+13.81%
- 2026-08-28China NMPA grants conditional approval for HUTCHMED's ATLED in oncologyHCM+13.81%
- 2026-08-28HUTCHMED Receives NMPA Conditional Approval for ATLED in ChinaHCM+13.81%
- 2026-06-12HUTCHMED Reports 66% Response Rate in Phase III Anemia TrialHCM-8.85%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.